ライフサイエンスコーパス: viral clearance

1 d early infection but were not essential for viral clearance.

2 ntributing to neuroinflammation and lowering viral clearance.

3 eks followed by a delayed seroconversion and viral clearance.

4 etween antibody levels and the efficiency of viral clearance.

5 Typically, inflammasome activation leads to viral clearance.

6 -DP to HBV-RT is not associated with delayed viral clearance.

7 or pegylated interferon-alpha can result in viral clearance.

8 ped along with the inflammatory response and viral clearance.

9 es to protection from immunopathology during viral clearance.

10 athy, while downregulation of MHC-I prevents viral clearance.

11 of soluble inflammatory mediators even after viral clearance.

12 evels of inflammatory cytokines, and delayed viral clearance.

13 nhanced viremia and inflammation and delayed viral clearance.

14 s (HCV) infection long after therapy-induced viral clearance.

15 dependent factors associated with POAE after viral clearance.

16 VLVL, 14% had a VLVL and 17% had spontaneous viral clearance.

17 nduction of autoimmunity as well as impaired viral clearance.

18 caused substantial RSV disease despite their viral clearance.

19 and mild hepatitis was observed, followed by viral clearance.

20 i-viral immune responses, leading to delayed viral clearance.

21 directly cleave viral DNA, thereby promoting viral clearance.

22 at adaptive T cell immunity is important for viral clearance.

23 owed a strong antiviral response and induced viral clearance.

24 ng ART concentrations in such sites enhances viral clearance.

25 f proinflammatory cytokines after successful viral clearance.

26 he identification of potential correlates of viral clearance.

27 lation and cytokine production) and enhanced viral clearance.

28 ar compartments and, as such, can facilitate viral clearance.

29 virus-specific T cells in order to expedite viral clearance.

30 LPR(-/-) mice enhanced morbidity and delayed viral clearance.

31 ic CD8(+) and CD4(+) T cells and inefficient viral clearance.

32 a antibodies that are critical for efficient viral clearance.

33 ce nor T-cell responses prior to spontaneous viral clearance.

34 r injury, shock, ventilation, mortality, and viral clearance.

35 pDC-dependent antibody production influences viral clearance.

36 specific T-cell responses, including in vivo viral clearance.

37 dinated immune response that is critical for viral clearance.

38 o be the most efficient antibody isotype for viral clearance.

39 (+) T and NK cells, which is associated with viral clearance.

40 ize liver damage by cytotoxic T cells during viral clearance.

41 delicate balance between immunopathology and viral clearance.

42 nues to drive a CD4(+) T cell response after viral clearance.

43 enous IFN-I rescues CD8(+)T cells, promoting viral clearance.

44 independent of other factors that may favour viral clearance.

45 of such complications but could also prolong viral clearance.

46 viral COPD exacerbation, which do not affect viral clearance.

47 e or during persistent infection can promote viral clearance.

48 cs for negating host immune surveillance and viral clearance.

49 tis B virus (HBV) infection is essential for viral clearance.

50 ) T cells reacting against donor only before viral clearance.

51 nate viral antigen-bearing cells and slowing viral clearance.

52 eningitis virus (LCMV) but have no impact on viral clearance.

53 needed in our model to explain the eventual viral clearance.

54 ith rejection before (9.1%) or after (26.0%) viral clearance.

55 cell (Teff) responses that are essential for viral clearance.

56 he involvement of the innate immune cells in viral clearance.

57 ing that class Ia molecules are required for viral clearance.

58 us graft loss due to BKVN preferably post-BK viral clearance.

59 8 enhances their immune effector function of viral clearance.

60 other persistent antagonists with the aim of viral clearance.

61 ed amplification assays were used to confirm viral clearance.

62 enance of RBV uptake may contribute to rapid viral clearance.

63 fic CD8 T cell immune response necessary for viral clearance.

64 tly decline in a manner suggestive of active viral clearance.

65 ns that indicate the possibility of eventual viral clearance.

66 survival, it was necessary for STAg-mediated viral clearance.

67 s C virus (HCV), associated with spontaneous viral clearance.

68 , 1.74; CI, 1.43-2.12) increased the rate of viral clearance.

69 he DOalpha F114L null allele was linked with viral clearance.

70 is, that result in greater airway damage and viral clearance.

71 ographic changes as a valuable predictor for viral clearance.

72 ociated with increased mortality and delayed viral clearance.

73 y6C)(+) monocytes and Kupffer cells (KCs) in viral clearance.

74 play an integral role in tumor rejection and viral clearance.

75 e HCV E2 envelope glycoprotein to facilitate viral clearance.

76 R 1.74; CI: 1.43-2.12) increased the rate of viral clearance.

77 ver, this did not suffice to yield sustained viral clearance.

78 re, associated with clinical improvement and viral clearance.

79 hampered pharmacological efforts to promote viral clearance.

80 bavirin alone for 4 months did not result in viral clearance.

81 e neutralizing viral particles and enhancing viral clearance.

82 of the central nervous system (CNS) despite viral clearance.

83 niche and remained in situ for months after viral clearance.

84 peptide-displaying cells and drive efficient viral clearance.

85 une response that may contribute to impaired viral clearance.

86 nt S. aureus coinfection, despite a delay in viral clearance.

87 te of recurrent infection and participate in viral clearance.

88 e responses are weak and thus rarely lead to viral clearance.

89 lls in the airways was associated with early viral clearance.

90 hepatitis B (AHB), which usually results in viral clearance.

91 adaptive immune response and accompanied by viral clearance.

92 henotype and suggesting their involvement in viral clearance.

93 to 3 weeks after infection due to failure of viral clearance.

94 target for long-term suppressive therapy or viral clearance.

95 restricting virus replication and promoting viral clearance.

96 potentiate both tumor immunosurveillance and viral clearance.

97 DeltaF508 mice demonstrated impaired viral clearance, a slower type I interferon response and

98 of HRCT scores for both disease severity and viral clearance, a standardised HRCT score system for CO

99 h their synergistic but spatially segregated viral clearance activities.

100 l immune responses and substantially delayed viral clearance after exposure to systemic LCMV or mucos

101 ing episodes during chronic HSV-2 infection; viral clearance always predominated within 24 hours of d

102 viral load in bronchial aspirates and faster viral clearance and a higher IFN-lambda to type I IFN ra

103 and effector functions, which may facilitate viral clearance and alleviate liver injury.

104 Viral clearance and associated immunopathology were meas

105 ects of the antibody are not limited to free viral clearance and blocking new infection but also incl

106 pivotal role in elevating host immunity for viral clearance and cancer immune surveillance.

107 e role of human APOBEC3-induced mutations in viral clearance and cervical carcinogenesis.

108 o a viral challenge and its association with viral clearance and clinical outcomes has been largely u

109 Here we describe that following viral clearance and clinical recovery, at 1 month after

110 erformed in the index patient at the time of viral clearance and compared with an OLT cohort with per

111 severe plasma leakage occurs at the time of viral clearance and defervescence in dengue hemorrhagic

112 ation, seen in wild type (WT) B6 mice, after viral clearance and demyelination.

113 persistence of T-cell activation well beyond viral clearance and detect EBOV-specific T cells.

114 viral immune response, which is critical for viral clearance and disease resolution.

115 nditional knockout mice also showed improved viral clearance and displayed enhanced expression of gra

116 WAS KO mice showed reduced viral clearance and enhanced immunopathology during LCMV

117 ion, and IKKepsilon expression and inhibited viral clearance and expression of genes required for ant

118 The precise role of these molecules in viral clearance and immune-mediated liver injury is not

119 es the CD8 T cell response, preventing early viral clearance and immunopathology associated with CD8

120 iral LRI, but the role of TCD8 impairment in viral clearance and immunopathology is unclear.

121 In the current study, viral clearance and inflammation resolution were indeed

122 ution of inflammation, with implications for viral clearance and lung pathology.

123 ties of IFN-lambda4 that can be important in viral clearance and other clinical conditions.

124 nti-preS1 response that results in efficient viral clearance and partial serological conversion in a

125 conclude that FOXO3a contributes to optimal viral clearance and prevents excessive lung inflammation

126 nt with a contribution of antibodies to both viral clearance and progression to severe disease.

127 innate and adaptive responses have a role in viral clearance and protection, they can also contribute

128 stinal pathogen, plays a significant role in viral clearance and protects against reinfection.

129 AECs and CD103+ DCs is crucial for effective viral clearance and recovery from injury, which has pote

130 owards the healthy ecostate, coinciding with viral clearance and recovery.

131 Viral clearance and SP-D/SP-A upregulation were unimpair

132 indings support a critical role of T-bet for viral clearance and suggest T-bet deficiency as an impor

133 piratory viral challenge, mediating enhanced viral clearance and survival to lethal influenza infecti

134 better understanding of mechanisms of early viral clearance and the development of approaches to ind

135 virulence of WNVKOU was associated with poor viral clearance and the induction of a poor neutralizing

136 CD8(+) T cells are important for viral clearance, and although often ineffective in neona

137 ducing increased migration to MLNs, enhanced viral clearance, and attenuated lung injury.

138 impaired antiviral CD8(+) T cell responses, viral clearance, and CD8(+) T cell-mediated host recover

139 This pathway might mediate viral clearance, and disruptions might be involved in th

140 rtance in shaping adaptive immune responses, viral clearance, and immune-based inflammation, tissue-s

141 Topical prednisolone acetate interfered with viral clearance, and ocular disease rebounded in prednis

142 hroughout the viral replication cycle, rapid viral clearance, and prevention of potentially harmful i

143 l respiratory tract infection, mechanisms of viral clearance, and the well-recognized consequences of

144 onic hepatitis E but become detectable after viral clearance; and (3) that HEV-specific T-cell respon

145 After the initial viral clearance, animals were rechallenged with SARS-CoV

146 ly 15%); and (iii) no visible papillomas and viral clearance ( approximately 65%).

147 obas CMV in 44.2% of patients at the time of viral clearance as determined by CAP/CTM CMV.

148 ng inflammation was more prevalent following viral clearance, as leukocyte numbers peaked at 14 days

149 We found that depletion of CD8 T cells after viral clearance, as well as blockade of NKG2D, reversed

150 Regardless of the viral clearance at the end of treatment, there was a sig

151 LR2-mediated immune response plays a role in viral clearance because wild-type mice cleared Candid 1

152 Despite viral clearance, bronchiolitis and alveolitis persisted

153 al cell shedding, which not only accelerates viral clearance but also contributes to acute obstructio

154 h CD4 and CD8 T cells not only contribute to viral clearance but also facilitate RSV-induced disease.

155 elucidate immune mechanisms that facilitate viral clearance but may also contribute to persistent lu

156 immunity that, on the one hand, can promote viral clearance, but alternately can increase necroinfla

157 ssion of vasculitis has been associated with viral clearance, but few studies have reported the effec

158 T cells rapidly undergo contraction upon viral clearance, but how T cell function and fate are de

159 T cells assist in viral clearance, but immune regulation serves to limit t

160 iciency enhanced T cell responses to promote viral clearance, but increased IL-22 in vivo decreased T

161 oinflammatory responses likely contribute to viral clearance, but prolonged exposure to proinflammato

162 IL-33, required for viral clearance by cytotoxic T cells, is generally expre

163 Viral clearance by day 5 and clinical responses were com

164 However, early viral clearance by IFN-I could limit antigen availabilit

165 We examined factors associated with viral clearance by month 4 including BKPyV-specific T ce

166 We examined the factors associated with viral clearance by Month 4, including BKPyV-specific T c

167 Rapid viral clearance by pegIFNalpha was confirmed in HEV gt1,

168 sults suggest that MPA preinfection inhibits viral clearance by suppressing the antiviral response pa

169 on immunosuppressive mechanisms that prevent viral clearance by the host.

170 tively inhibited HCV replication and induced viral clearance by the IFN-alpha+RBV combination treatme

171 nitored daily viral load kinetics, estimated viral clearance, calculated the half-life of the virus i

172 We propose that noncytopathic CNS viral clearance can be achieved by therapeutic antiviral

173 We showed that viral clearance can be achieved for high anti-HBV antibo

174 We further showed that viral clearance can be achieved for low equilibrium anti

175 ing downstream effector proteins, leading to viral clearance, cell dormancy or death.

176 germline Prkch (-/-) mice displayed enhanced viral clearance compared with control mice.

177 infected mice showed inefficient and delayed viral clearance compared with H1N1-infected mice.

178 ople who survive PML increases, this lack of viral clearance could create challenges in the subsequen

179 However, sustained viral clearance could not be achieved.

180 classified as non-virological failure since viral clearance could not be determined.

181 trol mice), neurological disease followed by viral clearance (Deltavhs infection of Stat1(-/-) mice a

182 sease severity but had no effect on eventual viral clearance, disease symptoms, or survival.

183 on alpha/beta (IFN-alpha/beta) is crucial to viral clearance during dengue virus (DENV) infection; ho

184 regulation of antiviral immune responses and viral clearance during IAV infection.IMPORTANCE The NOD-

185 F receptor blockade did not adversely affect viral clearance during influenza infection in mice.

186 pe I IFN (IFN-alpha) response is crucial for viral clearance during primary viral infections.

187 The relationships between RSV load, viral clearance dynamics, and disease severity have not

188 MPV-infected mice indicated that MDA5 alters viral clearance, enhances disease severity and pulmonary

189 CD8(+) T cells, were critical for mediating viral clearance, even in the presence of a functional in

190 f 4 with reinfection, demonstrated sustained viral clearance for a median of 26 months since last HCV

191 tically examines an emerging tool to measure viral clearance from biomanufacturing streams, monitor a

192 nce of nonneutralizing antibody functions in viral clearance from neurons.

193 Mutational analysis revealed that viral clearance from the circulation is strictly depende

194 illnesses of unknown origin for years after viral clearance from the circulation.

195 CD8+ cytotoxic T cells are critical for viral clearance from the lungs upon influenza virus infe

196 idity and mortality despite similar rates of viral clearance from the lungs.

197 RSV in sOP children may slow the kinetics of viral clearance from the nasopharynx and allow for viral

198 not interfere with antiviral Ab responses or viral clearance from the spleen, pancreatic lymph nodes,

199 nd that patients responding to IFNalpha with viral clearance had significantly higher serum levels of

200 Although ROS is necessary for optimal viral clearance, if not neutralized efficiently, it may

201 ated animals following challenge and delayed viral clearance in C3-deficient mice.

202 ron-gamma production, did not lead to faster viral clearance in CD40 transgenic mice.

203 and the relationship to disease severity and viral clearance in COVID-19 patients.

204 ransfer of wild-type CD8(+) T cells restored viral clearance in Cxcr3(-/-) animals.

205 h H1N1, H3N2, and H5N1 strains, and improved viral clearance in ferrets.

206 CD8(+) T cells, demonstrating that enhanced viral clearance in germline Prkch (-/-) mice is caused b

207 functional avidity have been associated with viral clearance in hepatitis C virus (HCV) infection and

208 e antigen B27 is associated with spontaneous viral clearance in hepatitis C virus (HCV) infection.

209 ously known, which presumably contributes to viral clearance in infected animals.

210 The increased inflammation and reduced viral clearance in IPS-1-knockout mice was accompanied b

211 rapy (LASER ART) and CRISPR-Cas9 demonstrate viral clearance in latent infectious reservoirs in HIV-1

212 acrophages deficient in Atf3 showed enhanced viral clearance in lymphocytic choriomeningitis virus an

213 for HEV RNA in stool and was detected after viral clearance in mice that were treated with ribavirin

214 t loss of IL-21 signaling results in reduced viral clearance in models of lymphocytic choriomeningiti

215 ute to progressive liver damage and impaired viral clearance in NASH.

216 immune response is associated with impaired viral clearance in Nlrc5(-/-) mice.

217 een associated with interferon (IFN)-induced viral clearance in patients with chronic hepatitis C.

218 This was supported by evidence of viral clearance in some animals and new infections in pr

219 ection, and this was associated with delayed viral clearance in the few surviving TRAIL(-/-) mice.

220 ge with LCMV-clone 13, resulting in impaired viral clearance in the liver.

221 response in nasal epithelium associates with viral clearance in the nasal compartment.

222 ence of WNVKOU also was associated with poor viral clearance in the periphery (sera and spleen), a sk

223 med, and Sel K(-/-) mice exhibited decreased viral clearance in the periphery and increased viral tit

224 inuum outcomes were self-reported except for viral clearance in treatment-experienced participants.

225 ly impacting autoimmune susceptibilities and viral clearance in vivo.

226 ower liver disease progression and increased viral clearance in women, the disease burden from HCV in

227 timicrobial responses, which led to impaired viral clearance, increased viral dissemination, and more

228 no skin T(RM) cells showed greatly impaired viral clearance, indicating that T(RM) cells provide sup

229 Viral clearance involves immune cell cytolysis of infect

230 ts into the role of host immune responses in viral clearance is critical for understanding COVID-19 p

231 se mild illness in healthy adults, as timely viral clearance is mediated by the functions of cytotoxi

232 equire efficient T cell responses to promote viral clearance, limit immunopathology, and enhance surv

233 basal autophagy, where the former acts as a viral clearance mechanism abrogating infection, while th

234 ic capacity is critical to understanding how viral clearance might be mediated by memory cells and wh

235 ences of IFN activation, while important for viral clearance, modify the host proinflammatory respons

236 fluenza infection, Egr2 CKO mice had delayed viral clearance, more weight loss, and more severe patho

237 Spontaneous viral clearance occurred in 29 of 37 (78.4%) patients an

238 Successful immunity to HBV is age dependent: viral clearance occurs in most adults, whereas neonates

239 ent inflammation in the absence of effective viral clearance occurs in VZV vasculopathy and VZV infec

240 ces heterosubtypic immunity that accelerates viral clearance of a second strain, even if the external

241 as the role of NKs in mediating IFN-induced viral clearance of chronic HCV infection.

242 (2:6)-infected mice, suggesting that delayed viral clearance of H5N1 (2:6) was due to the suppression

243 Robust viral clearance of HCV was observed in infected patients

244 orbidity and mortality without impairment in viral clearance or functional heterotypic immunity.

245 hough the contribution of individual NKRs to viral clearance or persistence remains to be clarified.

246 iral genome variations play a role in either viral clearance or persistence.

247 T cells play a crucial role in viral clearance or persistence; however, the precise mec

248 a new mechanism by which nanoART can enhance viral clearance over native drug formulations.

249 Viral loads were low in many cases and viral clearance rapid.

250 with increased SIV infectivity, a decreased viral clearance rate, increased viral load, and higher C

251 Viral clearance, reinfection, and intercalating infectio

252 sion of Ag-specific naive CD8(+) T cells and viral clearance remained fully intact.

253 ction, yet their contribution to spontaneous viral clearance remains controversial.

254 Viral clearance requires effector T-cell egress from the

255 function, resulting in significant tumor and viral clearance, respectively.

256 rent efforts to develop latency reversal and viral clearance strategies to eradicate established HIV

257 beginning to enter combination testing with viral clearance strategies.

258 revealed that migration is not required for viral clearance, suggesting a cytokine-mediated antivira

259 e activated during recovery, coincident with viral clearance, suggesting an important role of this ce

260 ed that asymptomatic participants had faster viral clearance than symptomatic participants (P < .001

261 allenged with RSV was associated with potent viral clearance that was mediated at least partly throug

262 es, with slopes reflecting the rate of serum viral clearance, the rate of loss of intracellular viral

263 However, after viral clearance, there was a subsequent approximately 50

264 ul to predict progression versus spontaneous viral clearance, thereby helping guide the need for anti

265 While T cells are indispensable for viral clearance, they also contribute to immunopathology

266 al to shaping the outcome of infection, from viral clearance to persistence.

267 lism by DGKs can serve a crucial function in viral clearance upon lymphocytic choriomeningitis virus

268 short time (HTST) treatment, a commonly used viral clearance upstream strategy.

269 While these interactions promote viral clearance via mainly neuroprotective mechanisms, t

270 tokines released by T cells also can promote viral clearance via noncytolytic processes.

271 or role in both tumor immunosurveillance and viral clearance via their effector functions.

272 CMI, the incidence of subsequent spontaneous viral clearance was 24 of 26 (92.3%) compared with 5 of

273 the two groups that received a loading dose--viral clearance was accelerated (P</=0.05), and the AUC

274 liver biopsies from SVR patients showed that viral clearance was accompanied by decreased expression

275 On-treatment viral clearance was accompanied by rapid downregulation

276 Viral clearance was achieved in three of the four patien

277 Interestingly, faster viral clearance was associated with a >/=4-fold NAb resp

278 ntaneous, but not antiviral therapy-induced, viral clearance was associated with increased antiviral

279 RSV compared with nonallergic mice, whereas viral clearance was comparable in both mouse groups.

280 The association of age with viral load and viral clearance was examined by determining the area und

281 Moreover, viral clearance was impaired in UNC93B1 mutant mice, des

282 No further compromise of viral clearance was observed when DCs were continuously

283 Similarly, viral clearance was rescued upon restored IPS-1 signalin

284 Because viral clearance was unimpaired, the study highlights the

285 le for Ag presentation persistence following viral clearance was unknown until now.

286 ce normally resistant to TMEV infection with viral clearance, we have previously demonstrated that RO

287 Temporal radiographic changes and viral clearance were explored using appropriate statisti

288 Antiviral CD8(+) T cell responses and viral clearance were impaired in miR-155-deficient mice,

289 during viral infection to promote efficient viral clearance while limiting immunopathology.

290 ptimal immunosuppressive regimens, to enable viral clearance while preventing rejection and donor-spe

291 ffectors at the site of infection to promote viral clearance, while decreasing the numbers of bystand

292 tes of tumor recurrence and occurrence after viral clearance with DAA agents.

293 ted with attenuated weight loss and enhanced viral clearance with primary challenge in STAT4-/- mice

294 4] vs 217 [44.6], p<0.001); it also impaired viral clearance, with increased lung tissue viral RNA co

295 e receptors continued to increase even after viral clearance, with most virus-specific lung TCD8 expr

296 response, leading to clinical resolution and viral clearance, with no evidence of acquired drug resis

297 luticasone and rhinovirus alone and improved viral clearance without having any effect on suppression

298 ction resulting in three different outcomes: viral clearance without neurological disease (Deltavhs i

299 cific T cell response, resulting in impaired viral clearance, without affecting CD4 T cell responses.

300 virally infected CNS is vital for promoting viral clearance yet may contribute to neuropathology if